Dengvaxia®
Company
Sanofi
Use
Prevention of dengue disease in individuals 9-16 years old with prior dengue infection.
Features
A tetravalent vaccine against four serotypes of the dengue virus. FDA approved in 2019.
NIH Contribution
NIH research on dengue virus vaccines
HHS Institute/Agency
NIAID
Inventor(s)
Lai, C-J. et al.
Year
2019
